Adjuvant atezolizumab in surgically resected NSCLC patients with PD-L1 expression ≥ 50%: real-world data from the Italian ATLAS registry.

Passiglia F, Reale ML, Pasello G, Viscardi G, Attili I, Mazzoni F, Galetta D, Catania C, Andrikou K, Russo A, Vavala T, Bulotta A, Calvetti L, Carta AM, Grisanti S, Mariotti S, La Cava G, Dodi A, Scotti V, Del Giudice T, Minuti G, Pizzutillo EG, Chiari R, Della Corte CM, Genova C, Lo Russo G, Pignataro D, Pozzessere D, Roca E, Toschi L, Bennati C, Borra G, Bettini A, Favaretto A, Gelibter A, Gori S, Tabbò F, Pagano M, Pavan A, Belluomini L, Tondulli L, Sergi C, Stanzione B, Malapelle U, Novello S, Bria E

Open source

DOI
10.1093/oncolo/oyaf428
Published
2026 Jan 17
Container
The oncologist
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1093/oncolo/oyaf428,
  title = {Adjuvant atezolizumab in surgically resected NSCLC patients with PD-L1 expression ≥ 50\%: real-world data from the Italian ATLAS registry.},
  author = {Passiglia F and Reale ML and Pasello G and Viscardi G and Attili I and Mazzoni F and Galetta D and Catania C and Andrikou K and Russo A and Vavala T and Bulotta A and Calvetti L and Carta AM and Grisanti S and Mariotti S and La Cava G and Dodi A and Scotti V and Del Giudice T and Minuti G and Pizzutillo EG and Chiari R and Della Corte CM and Genova C and Lo Russo G and Pignataro D and Pozzessere D and Roca E and Toschi L and Bennati C and Borra G and Bettini A and Favaretto A and Gelibter A and Gori S and Tabbò F and Pagano M and Pavan A and Belluomini L and Tondulli L and Sergi C and Stanzione B and Malapelle U and Novello S and Bria E},
  year = {2026},
  journal = {The oncologist},
  doi = {10.1093/oncolo/oyaf428},
  url = {https://doi.org/10.1093/oncolo/oyaf428}
}

RIS

TY  - JOUR
TI  - Adjuvant atezolizumab in surgically resected NSCLC patients with PD-L1 expression ≥ 50%: real-world data from the Italian ATLAS registry.
AU  - Passiglia F
AU  - Reale ML
AU  - Pasello G
AU  - Viscardi G
AU  - Attili I
AU  - Mazzoni F
AU  - Galetta D
AU  - Catania C
AU  - Andrikou K
AU  - Russo A
AU  - Vavala T
AU  - Bulotta A
AU  - Calvetti L
AU  - Carta AM
AU  - Grisanti S
AU  - Mariotti S
AU  - La Cava G
AU  - Dodi A
AU  - Scotti V
AU  - Del Giudice T
AU  - Minuti G
AU  - Pizzutillo EG
AU  - Chiari R
AU  - Della Corte CM
AU  - Genova C
AU  - Lo Russo G
AU  - Pignataro D
AU  - Pozzessere D
AU  - Roca E
AU  - Toschi L
AU  - Bennati C
AU  - Borra G
AU  - Bettini A
AU  - Favaretto A
AU  - Gelibter A
AU  - Gori S
AU  - Tabbò F
AU  - Pagano M
AU  - Pavan A
AU  - Belluomini L
AU  - Tondulli L
AU  - Sergi C
AU  - Stanzione B
AU  - Malapelle U
AU  - Novello S
AU  - Bria E
PY  - 2026
JO  - The oncologist
DO  - 10.1093/oncolo/oyaf428
UR  - https://doi.org/10.1093/oncolo/oyaf428
ER  -

APA

F, P., ML, R., G, P., G, V., I, A., F, M., D, G., C, C., K, A., A, R., T, V., A, B., L, C., AM, C., S, G., S, M., G, L. C., A, D., V, S., T, D. G., G, M., EG, P., R, C., CM, D. C., C, G., G, L. R., D, P., D, P., E, R., L, T., C, B., G, B., A, B., A, F., A, G., S, G., F, T., M, P., A, P., L, B., L, T., C, S., B, S., U, M., S, N., & E, B. (2026). Adjuvant atezolizumab in surgically resected NSCLC patients with PD-L1 expression ≥ 50%: real-world data from the Italian ATLAS registry.. The oncologist. https://doi.org/10.1093/oncolo/oyaf428

Source records